These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28306392)

  • 41. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT.
    Kniggendorf VF; Novais EA; Kniggendorf SL; Xavier C; Cole ED; Regatieri CV
    Arq Bras Oftalmol; 2016; 79(3):155-8. PubMed ID: 27463625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
    Horsley MB; Mandava N; Maycotte MA; Kahook MY
    Am J Ophthalmol; 2010 Oct; 150(4):558-561.e1. PubMed ID: 20643396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Kim M; Kim K; Kim DG; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
    Krohne TU; Muether PS; Stratmann NK; Holz FG; Kirchhof B; Meyer CH; Fauser S
    Retina; 2015 Jan; 35(1):69-74. PubMed ID: 25077535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bimanual assisted eyelid retraction technique for intravitreal injections.
    Fineman MS; Hsu J; Spirn MJ; Kaiser RS
    Retina; 2013 Oct; 33(9):1968-70. PubMed ID: 23609121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
    Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ARE INTRAVITREAL INJECTIONS WITH ULTRATHIN 33-G NEEDLES LESS PAINFUL THAN THE COMMONLY USED 30-G NEEDLES?
    van Asten F; van Middendorp H; Verkerk S; Breukink MB; Lomme RM; Hoyng CB; Evers AW; Klevering BJ
    Retina; 2015 Sep; 35(9):1778-85. PubMed ID: 25901838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival of Hepatitis C Virus in Syringes Is Dependent on the Design of the Syringe-Needle and Dead Space Volume.
    Binka M; Paintsil E; Patel A; Lindenbach BD; Heimer R
    PLoS One; 2015; 10(11):e0139737. PubMed ID: 26536599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of commonly used intravitreal anti-vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body.
    Acar U; Erginturk Acar D; Alpaslan Pinarli F; Demir MN; Beyazyildiz E; Ozdemir O; Gulmez Sevim D; Tiryaki M; Sobaci G
    Clin Exp Ophthalmol; 2016 Sep; 44(7):587-596. PubMed ID: 26856706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
    Good TJ; Kimura AE; Mandava N; Kahook MY
    Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigation of Two Prototypes of Novel Noncontact Technologies for Automated Real-Time Capture of Incremental Drug Administration Data From Syringes.
    Eagle B; Williams DJ; Dingley J
    Anesth Analg; 2017 Aug; 125(2):458-466. PubMed ID: 28632533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
    Fauser S; Muether PS
    Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
    Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
    Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experimental investigation of needles, syringes and techniques for intravitreal injections.
    De Stefano VS; Abechain JJ; de Almeida LF; Verginassi DM; Rodrigues EB; Freymuller E; Maia M; Magalhaes O; Nguyen QD; Farah ME
    Clin Exp Ophthalmol; 2011 Apr; 39(3):236-42. PubMed ID: 20973898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of the risk of needlestick injuries associated with intravitreal injections.
    Shah SU; Koenig MJ; Dacquay Y; Mozayan A; Hubschman JP
    Retina; 2014 Apr; 34(4):781-4. PubMed ID: 23975000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
    Nuzzi R; Tridico F
    Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Association between Needle Size and Waste Product and Its Effect on Cost-Effectiveness of Botulinum Toxin Injections?
    Golan S; Pena J; Moore J; Tandalam S; Lelli G
    Facial Plast Surg; 2020 Aug; 36(4):484-486. PubMed ID: 32688397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
    Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
    Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.